Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04076462 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Phase 3 study of Acromegaly, sponsored by Camurus AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT04076462 is a Phase 3 study of Acromegaly that has completed, run by Camurus AB. The registered enrollment target is 72 participants, below the 96-participant average among 13 other Acromegaly trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04076462, a Phase 3 study of Acromegaly, has completed, sponsored by Camurus AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
Conditions Studied
Interventions
- DRUG Matching placebo
- DRUG CAM2029 (octreotide subcutaneous depot)
Study Locations (20)
Other
- Universitätsklinikum Essen - Essen
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Schwerpunkt Endokrinologie, Diabetologie, Ernährungsmedizin - Frankfurt
- Universitätsklinikum Freiburg - Freiburg im Breisgau
- LMU Clinic of University of Munich, Medical Clinic and Polyclinic IV - Munich
- Medicover Neuroendokrinologie - Munich
- Medicover Oldenburg MVZ - Oldenburg
- General Hospital of Athens "Laiko", Endocrinology University Clinic - Athens
- Aretaeio University Hospital Endocrinology Department, Faculty of Diabetes and Metabolism - Athens
California
- UCLA Department of Medicine Division of Endocrinology - Los Angeles
- Stanford University Medical Center - Palo Alto
Pennsylvania
- Thomas Jefferson University - Philadelphia
- Allegheny Endocrinology Associates - Pittsburgh
Florida
- Prufen Clinical Research LLC - Miami
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University in St. Louis, School of Medicine - St Louis
Nevada
- Palm Research Center - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2023-05-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04076462
The ClinicalTrials.gov registry entry for NCT04076462 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 13 other Acromegaly trials with a reported enrollment target (25% lower). The listed sponsor is Camurus AB, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Matching placebo is the first listed.
NCT04076462 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04076462 about?
NCT04076462 is a clinical study titled "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly". The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
What is the current status of trial NCT04076462?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2019-08-19. Estimated completion is 2023-05-02.
What conditions does trial NCT04076462 study?
This clinical trial studies the following conditions: Acromegaly.
What interventions are being tested in trial NCT04076462?
The interventions under investigation include: Matching placebo (DRUG), CAM2029 (octreotide subcutaneous depot) (DRUG).
Who is sponsoring clinical trial NCT04076462?
This trial is sponsored by Camurus AB, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04076462 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
ACTIVE NOT RECRUITING · Phase 3
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.